Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PABPC1 | P11940 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temozolomide SCHEMBL3739 | 1.00 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL4746638 | 0.98 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3784250 | 0.98 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL28275477 | 0.98 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL1534013 | 0.98 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL27721442 | 0.94 | MEN1 (0.89) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL16227379 | 0.91 | MEN1 (0.82) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL10168201 | 0.90 | MEN1 (0.81) | MEN1PABPC1KMT2ACA12CA1 | |
| Altretamine SCHEMBL27875070 | 0.89 | KMT2A (0.80) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL4444959 | 0.88 | MEN1 (0.78) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019024784-A1 | FATTY ACID CONJUGATED NANOPARTICLES AND USES THEREOF | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2019-02-07 | — | — | WO | claimed |
| US-20190029970-A1 | FATTY ACID CONJUGATED NANOPARTICLES AND USES THEREOF | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2019-01-31 | — | — | US | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| CN-112262156-B | Anti-HER 2 antibodies | 新加坡科技研究局 | 2024-07-05 | — | — | CN | disclosed |
| US-20230181534-A1 | USE OF A PROTEASOME INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS | CELGENE INT II SARL (CH) | 2023-06-15 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10683338-B2 | Single-chain TL1A receptor agonist proteins | APOGENIX AG (DE) | 2020-06-16 | — | — | US | disclosed |
| US-20200085789-A1 | USE OF A PROTEASOME INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS | CELGENE INT II SARL (CH) | 2020-03-19 | — | — | US | disclosed |
| EP-3080341-B1 | METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA INC (US) | 2020-02-12 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019040724-A1 | SMALL MOLECULE INHIBITORS OF MYC AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-28 | — | — | WO | disclosed |
| EP-2970965-A2 | DNAI FOR THE MODULATION OF GENES | Pronai Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150160246-A1 | DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014144942-A2 | DNAI FOR THE MODULATION OF GENES | PRONAI THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013119923-A1 | DIFFERENT STATES OF CANCER STEM CELLS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-08-15 | — | — | WO | disclosed |
| CN-102497864-A | Sigma ligands for the prevention or treatment of pain induced by chemotherapy | ESTEVE LABOR DR | 2012-06-13 | — | — | CN | disclosed |
| EP-1934224-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |
| WO-2007139556-A1 | COMBINATION OF CHEMOTHERAPEUTIC COMPOUNDS FOR TREATING CANCER | REATA PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-1549742-A1 | METHOD FOR SELECTION OF COMPOUNDS WHICH INHIBIT CLONAL CELL GROWTH AND USE THEREOF | Tjötta, Enok (NO) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004055175-A1 | METHOD FOR SELECTION OF COMPOUNDS WHICH INHIBIT CLONAL CELL GROWTH AND USE THEREOF | TJOETTA ENOK (NO) | 2004-07-01 | — | — | WO | disclosed |